UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial

Kanhai, KMS; Nij Bijvank, JA; Wagenaar, YL; Klaassen, ES; Lim, K; Bergheanu, SC; Petzold, A; ... Groeneveld, GJ; + view all (2019) Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial. CNS Neuroscience and Therapeutics 10.1111/cns.13096. (In press). Green open access

[thumbnail of Kan2019_ - Treatment of Internuclear Ophthalmoparesis in Multiple Sclerosis with Fampridine_ a Randomized Double Blind, Placebo Controlled Cross Over Trial..pdf]
Preview
Text
Kan2019_ - Treatment of Internuclear Ophthalmoparesis in Multiple Sclerosis with Fampridine_ a Randomized Double Blind, Placebo Controlled Cross Over Trial..pdf - Published Version

Download (670kB) | Preview

Abstract

AIM: To examine whether the velocity of saccadic eye movements in internuclear ophthalmoparesis (INO) improves with fampridine treatment in patients with multiple sclerosis (MS). METHODS: Randomized, double-blind, placebo-controlled, cross-over trial with fampridine in patients with MS and INO. Horizontal saccades were recorded at baseline and at multiple time points post-dose. Main outcome measures were the change of peak velocity versional dysconjugacy index (PV-VDI) and first-pass amplitude VDI (FPA-VDI). Both parameters were compared between fampridine and placebo using a mixed model analysis of variance taking patients as their own control. Pharmacokinetics was determined by serial blood sampling. RESULTS: Thirteen patients had a bilateral and 10 had a unilateral INO. One patient had an INO of abduction (posterior INO of Lutz) and was excluded. Fampridine significantly reduced both PV-VDI (-17.4%, 95% CI: -22.4%, -12.1%; P < 0.0001) and FPA-VDI (-12.5%, 95% CI: -18.9%, -5.5%; P < 0.01). Pharmacokinetics demonstrated that testing coincided with the average tmax at 2.08 hours (SD 45 minutes). The main adverse event reported after administration of fampridine was dizziness (61%). CONCLUSION: Fampridine improves saccadic eye movements due to INO in MS. Treatment response to fampridine may gauge patient selection for inclusion to remyelination strategies in MS using saccadic eye movements as primary outcome measure.

Type: Article
Title: Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/cns.13096
Publisher version: https://doi.org/10.1111/cns.13096
Language: English
Additional information: © 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: fampridine, internuclear ophthalmoplegia, multiple sclerosis, video-oculography
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
URI: https://discovery.ucl.ac.uk/id/eprint/10068807
Downloads since deposit
96Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item